Popular terms

Antibodies topics
Antibodies
Recombinant
Nucleic Acid
Nucleic Acids
Polypeptide
Therapeutics
Immunoglobulin
Immunoglobulins
Monoclonal
Radiation Therapy
Desmoplastic
Hypertension
Hypertensive
Immunotherapy
Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antibodies patents



      

This page is updated frequently with new Antibodies-related patent applications.




Date/App# patent app List of recent Antibodies-related patents
07/14/16
20160202271 
 Test paper for detection of diabetic nephropathy patent thumbnailTest paper for detection of diabetic nephropathy
Disclosed is a test paper for detection of diabetic nephropathy, which includes a water-absorbing filter paper, a glass fiber membrane and a nc membrane, all of which are stacked successively from top to bottom. The test paper has a t1 testing region, a t2 testing region and a t3 reference region arranged along a transverse direction; the nc membrane is coated by urinary microalbumin antibodies in the t1 testing region, is coated by urinary haptoglobin antibodies in the t2 testing region and is coated by mouse anti-human igg antibodies in the t3 reference region; and the glass fiber membrane is coated by urinary microalbumin labeled with colloidal gold in the t1 testing region, is coated by urinary haptoglobin labeled with colloidal gold in the t2 testing region and is coated by mouse anti-human igg albumen labeled with colloidal gold in the t3 reference region..
Shenzhen Leadmed Medical Technology Company Limited


07/14/16
20160202265 
 Method of determining resistance to influenza virus patent thumbnailMethod of determining resistance to influenza virus
Provided is a method of providing an effective means as a countermeasure for handling a pandemic of an influenza virus. The resistance to a type a influenza virus is determined using, as an indicator, the presence or otherwise of antibodies using the vh1-69 gene in a biological sample originating from a subject..
Fujita Health University


07/14/16
20160202245 
 Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells patent thumbnailMeans and methods for the determination of the biological activity of neurotoxin polypeptides in cells
The present invention pertains to a method for directly determining the biological activity of a neurotoxin polypeptide in cells, comprising the steps of: a) incubating cells susceptible to neurotoxin intoxication with a neurotoxin polypeptide for a time and under conditions which allow for the neurotoxin polypeptide to exert its biological activity; b) fixing the cells and, optionally, permeabilizing the cells with a detergent; c) contacting the cells with at least a first capture antibody specifically binding to the non-cleaved and neurotoxin-cleaved substrate and with at least a second capture antibody specifically binding to the cleavage site of the neurotoxin-cleaved substrate, under conditions which allow for binding of said capture antibodies to said substrates; d) contacting the cells with at least a first detection antibody specifically binding to the first capture antibody, under conditions which allow for binding of said first detection antibody to said first capture antibody, thus forming first detection complexes, and at least a second detection antibody specifically binding to the second capture antibody, under conditions which allow for binding of said second detection antibody to said second capture antibody, thus forming second detection complexes; e) determining the amount of the first and second detection complexes of step d), and f) calculating the amount of substrate cleaved by said neurotoxin polypeptide in said cells by means of the second detection complexes, thereby determining the biological activity of said neurotoxin polypeptide in said cells. The invention further provides for a kit for carrying out the method of the invention..
Merz Pharma Gmbh & Co. Kgaa


07/14/16
20160201082 
 Axmi422 toxin gene and methods for its use patent thumbnailAxmi422 toxin gene and methods for its use
Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided.
Athenix Corp.


07/14/16
20160201054 
 Method of obtaining antibodies of interest and nucleotides encoding same patent thumbnailMethod of obtaining antibodies of interest and nucleotides encoding same
The invention is a methodology which makes it possible to select from a very large number of cells, a single cell or cells of interest and obtain specific information from those cells in a rapid and efficient manner. As an example of the methodology, a large number of antibody producing cells such as plasma cells are separated so that these individual antibody producing plasma cells are placed in individual wells.
Single Cell Technology, Inc.


07/14/16
20160201053 
 Inducible mutagenesis of target genes patent thumbnailInducible mutagenesis of target genes
The present invention relates generally to mutagenesis of target genes that takes advantage of the natural mutagenic capabilities of b cells, and enhances those capabilities by bringing the process of diversification under control. The invention provides a method for rapidly and inducibly generating point mutations and other types of diversification in expressed genes, such as antibody genes.
University Of Washington


07/14/16
20160200847 
 Clickable polymers and gels for  microarray and other applications patent thumbnailClickable polymers and gels for microarray and other applications
Fabrication of arrays, including glycan arrays, that combines the higher sensitivity of a layered si—sio2 substrate with novel immobilization chemistry via a “click” reaction. The novel immobilization approach allows the oriented attachment of glycans on a “clickable” polymeric coating.

07/14/16
20160200834 
 Antibody and recombinant derivative for the detection of trinitrotoluene patent thumbnailAntibody and recombinant derivative for the detection of trinitrotoluene
Described herein are new recognition elements (antibodies or functional fragments thereof) that effectively bind to trinitrotoluene (tnt). Also disclosed is a single chain fragment recognition element..
The Government Of The United States Of America, As Represented By The Secretary Of The Navy


07/14/16
20160200832 
 Assay to detect human dpp-4 patent thumbnailAssay to detect human dpp-4
This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of dpp-4 levels in samples obtained from human patients. The disclosure further provides novel anti-dpp-4 monoclonal antibodies that recognize human dpp-4, and assay kits comprising one or more of these antibodies..
Medimmune, Llc


07/14/16
20160200831 
 Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof patent thumbnailAntibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
The invention provides antibodies that specifically bind to plasminogen activator inhibitor type-1 (pai-1), the invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-pai-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate pai-1 activity or detect pai-1, either in vitro or in vivo, are also provided.
Sanofi


07/14/16
20160200830 

Compositions and methods for increasing protein half-life in a serum


Novel antibodies, such as single domain antibodies (sdabs), or fragments thereof that specifically bind a transferrin are described. Compositions, methods and systems for increasing the half-life of a target protein in a serum using an antibody or fragment thereof against a transferrin are described..
Nanjingjinsirui Science & Technology Biology Corporation


07/14/16
20160200828 

Anti-cd38 human antibodies and uses thereof


The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for cd38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma.
Morphosys Ag


07/14/16
20160200826 

Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof


This invention relates generally to the generation of antibodies, e.g., monoclonal antibodies including fully human monoclonal antibodies, that recognize jagged 1 and/or jagged 2, to antibodies, e.g., monoclonal antibodies including fully human antibodies that recognize jagged 1 and/or jagged 2, and nucleic acid molecules that encode antibodies, e.g., nucleic acid molecules that encode monoclonal antibodies including fully human cross-reactive antibodies that recognize both jagged 1 and jagged 2, and to methods of making the anti-jagged antibodies and methods of using the anti-jagged antibodies as therapeutics, prophylactics, and diagnostics. The invention also relates generally to activatable antibodies that include a masking moiety (mm), a cleavable moiety (cm), and an antibody (ab) that specifically bind to jagged 1 and jagged 2, and to methods of making and using these activatable anti-jagged antibodies in a variety of therapeutic, diagnostic and prophylactic indications..
Cytomx Therapeutics, Inc.


07/14/16
20160200825 

Cells producing fc-containing molecules having altered glycosylation patterns and methods and use thereof


The present application relates to the field of glyco-engineering, more specifically to glyco-engineering of fc-containing molecules, such as antibodies. It is shown herein that fc-containing molecules with a specific glycosylation pattern have a considerably longer circulating half-life in vivo, without having an altered binding affinity for their respective antigen.
Universiteit Gent


07/14/16
20160200823 

Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof


This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a cd154 (cd40l) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized fab fragment comprising a variable heavy chain sequence according to seq id no: 1 and comprising a variable light chain sequence according to seq id no: 2 specifically binds.
Biogen Idec Ma Inc.


07/14/16
20160200822 

Antibodies which bind type i cannabinoid receptor/angiotensis ii receptor heteromers


Compounds and compositions useful for the treatment of liver diseases and methods of treating liver diseases are disclosed. The compounds of the invention specifically interact with heteromers of cannabinoid receptors as compared to monomers or homodimers.
Icahn School Of Medicine At Mount Sinai


07/14/16
20160200821 

Antibodies


The present invention relates to an anti-csf-1r antibody and binding fragments thereof, dna encoding the same, host cells comprising said dna and methods of expressing the antibody or binding fragment in a host cell. The present invention also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment..
Ucb Biopharma Sprl


07/14/16
20160200819 

Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer


The invention provides chimeric antigen receptors (cars) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain t cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the cars are disclosed.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


07/14/16
20160200817 

Methods of identifying anti-inflammatory compounds


A mammalian c-type lectin receptor type is identified which is shown to bind igg antibodies or fc fragments, thus inducing ivig-related reversal of inflammation associated with various immune disorders. The identification of a dc-sign receptor type which interacts with igg to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a dc-sign(+) cell to signal a second effector macrophage, causing an increase in expression of the fcγriib receptor and in turn inhibiting a cellular-mediated inflammatory response..
The Rockefeller University


07/14/16
20160200815 

Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof


Provided herein are embodiments relating to therapeutic applications of antibodies that modulate; e.g., inhibit the interaction of tim-3 and lilrb2 antibodies. In some embodiments, the antibodies bind tim-3.
Jounce Therapeutics, Inc.


07/14/16
20160200807 

Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use


The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided.
Chugai Seiyaku Kabushiki Kaisha


07/14/16
20160200806 

Vegf-binding molecules


Vegf-binding molecules, preferably vegf-binding immunoglobulin single variable domains like vhhs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with vegf-mediated effects on angiogenesis. Nucleic acids encoding vegf-binding molecules, host cells and methods for preparing same..
Boehringer Ingelheim International Gmbh


07/14/16
20160200804 

Compositions and methods for treating anaplastic thyroid cancer


Methods of treating a disease or disorder characterized by cells with increased or aberrant expression of cytokeratin-8 (ck8) are disclosed. The methods typically include administering to a subject in need thereof a pharmaceutical composition including an effective amount of a ck8 inhibitor.
H. Lee Moffitt Cancer Center And Research Institute, Inc.


07/14/16
20160200803 

Monoclonal antibodies that neutralize anthrax toxins


The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (lf), edema factor (ef), and/or protective antigen (pa). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies.

07/14/16
20160200802 

Antibodies that potently neutralize rsv and uses thereof


The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both group a and group b rsv. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized b cells and cultured plasma cells that produce such antibodies and antibody fragments.
Humabs Biomed Sa


07/14/16
20160200801 

Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes


Monoclonal antibodies directed against the influenza a virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza a virus. One preferred embodiment is the antibody designated as fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza a virus.
Pomona Ricerca S.r.l.


07/14/16
20160200800 

Antibodies directed against influenza


antibodies that specifically bind influenza virus hemagglutinin a (ha), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing.
The University Of Chicago


07/14/16
20160200797 

Chromatography ligand comprising domain c from staphylococcus aureus protein a for antibody isolation


The present invention relates to a chromatography ligand, which comprises domain c from staphylococcus protein a (spa), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (cip) conditions, and is capable of binding fab fragments of antibodies.
Ge Healthcare Bio-sciences Ab


07/14/16
20160200793 

Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy


The present invention provide purified flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.. .
Vegenics Pty Limited


07/14/16
20160200789 

Il4 conjugated to antibodies against extracellular matrix components


A conjugate comprising interleukin-4 (il4) and a specific binding member is disclosed. The specific binding member preferably binds an extra-cellular matrix component associated with neoplastic growth and/or angiogenesis, and the conjugate may be used for targeting il4 to tissues in vivo.
Philogen S.p.a.


07/14/16
20160199524 

Radiosensitivity of fluorophores and use of radioprotective agents for dual-modality imaging


The present application discloses compositions and methods of use of dual-labeled molecules comprising a fluorescent probe and a radionuclide. The labeled molecules are of use for detection, imaging and/or diagnosis of diseased tissues, such as tumors.
Immunomedics, Inc.


07/14/16
20160199522 

Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders


Methods for detecting α-synuclein oligomers in vivo comprise administering an antibody to an individual suspected of carrying soluble α-synuclein, wherein the antibody is produced from a stabilized soluble α-synuclein oligomer and is capable of binding the stabilized soluble α-synuclein oligomer, wherein the stabilized soluble α-synuclein oligomer has a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the α-synuclein, and wherein the antibody is labelled with a detectable marker; and detecting the presence of any complex formed between the antibody and soluble α-synuclein by detection of the marker.. .
Bioarctic Neuroscience Ab


07/14/16
20160199508 

Anti-ly6e antibodies and immunoconjugates and methods of use


The invention provides anti-ly6e antibodies, immunoconjugates and methods of using the same.. .
Genentech, Inc.


07/14/16
20160199494 

Compositions and methods for stabilizing protein-containing formulations


The present invention relates to use of certain alkylglycoside compositions for the prevention of aggregation and oxidation of antibodies and other proteins in therapeutically useful formulations thereof.. .
Genentech, Inc.


07/14/16
20160199468 

Inotropic antibodies and therapeutic uses thereof


antibodies binding to sites on the alpha-subunit of the (na++k+)-atpase increase cardiac contraction of both ventricular myocytes and mouse heart. In particular, antibodies binding to the rsateeeppndd (seq id no: 1) or dvedsygqqtyeqr (seq id no: 2) peptides (or isoforms/derivatives thereof) of the alpha-subunit of the (na++k+)-atpase, have been found to be highly inotropic.

07/14/16
20160199442 

Anti- p2x7 peptides and epitopes


The invention relates to the identification of a novel epitope on non-function p2x7 receptors which are implicated in cancer. The epitope includes a region from two adjacent monomers within the three subunit receptor.
Biosceptre (aust) Pty Ltd


07/07/16
20160195546 

Type 1 diabetes biomarkers


Type 1 diabetes (t1d) patients make antibodies to self-proteins that are potential biomarkers for early detection and risk prediction. We have identified seventeen antigens as biomarkers for early diagnosis and risk prediction of t1d, including the antigens mlh1, mtif3, ppil2, nup50, tox4, fign, c9orf142, znf280d, hes1, qrfpr, ctrc, snx6, sytl4, ela2a, igrp, pax6, and hmgn3..
University Of Florida Research Foundation, Incorporated


07/07/16
20160195545 

Assay for nitrated and total hemopexin in fluid samples


A method of detecting and measuring the level of total hemopexin and nitrated hemopexin in a sample of a patient in need thereof, wherein increased levels of nitrated hemopexin, relative to total hemopexin in samples, are indicative of inactivated hemopexin leading to heme toxicity and oxidative stress. In particular, the method uses an elisa for total and nitrated hemopexin.

07/07/16
20160195538 

Compositions and methods for detecting, diagnosing, and treating cancer


The present invention provides compositions and methods useful for diagnosing, treating, and preventing cancer, particularly ovarian cancer and uterine cancer, based on the discovery that the oocyte specific protein, sas1r (sperm acrosomal sllp1 receptor), which is a sperm protein receptor, is also expressed in various cancers, including ovarian cancer and uterine cancer. Six sas1r variants have been previously identified, and they are encompassed by the invention.
University Of Virginia Patent Foundation


07/07/16
20160195527 

Borrelia diagnostics and screening methods


The present invention provides methods of detecting borrelia species in a sample (e.g., a sample from a patient suspected of being infected). In particular, the present invention provides compositions and methods for detecting the presence of borrelia proteins, nucleic acid sequences encoding these proteins, and subject antibodies to these proteins, where the proteins are selected from those listed in table 3, including: bb0279 (flil), bbk19, bbk07, bb0286 (flbb), bbg33, bbl27, bbn34, bbp34, bbq42, bbq34, bbm34, bbn27, and bbh13..
The Regents Of The University Of California


07/07/16
20160194627 

Combinatorial antibody libraries and uses thereof


Methods for making a combinatorial antibody library from human germline segments are provided. Also provided are libraries of nucleic acid molecules compiled from germline segments encoding vl chains and libraries of nucleic acid molecules encoding vh chains, and resulting antibody libraries.
Fabrus, Inc.


07/07/16
20160194408 

Anti-pcsk9 antibodies and use thereof


The present invention is directed to antibodies and fragments thereof having binding specificity for pcsk9. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the vh, vl and cdr polypeptides described herein, and the polynucleotides encoding them.
Alderbio Holdings Llc


07/07/16
20160194407 

Binding molecules specific for cd73 and uses thereof


The present disclosure provides anti-cd73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with cd73-expression, e.g., cancer.
Medimmune Limited


07/07/16
20160194405 

Anti-tissue factor antibodies and compositions


Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced adcc activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced adcc activity.
Janssen Biotech, Inc.


07/07/16
20160194399 

Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same


The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least cd3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.. .
Cytomx Therapeutics, Inc.


07/07/16
20160194398 

Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer


This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the a33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.. .
Precision Biologics, Inc.


07/07/16
20160194394 

Antibodies against frizzled proteins and methods of use thereof


This invention provides monoclonal antibodies that recognize one or more frizzled receptors. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic..
The Governing Council Of The University Of Toronto


07/07/16
20160194392 

Antibodies against il-1 beta


The present invention relates to anti-il-1 beta antibodies and in particular to monovalent high potency il-1 beta-binding antibody fragments being highly stable. Such antibodies can be used in the treatment of inflammatory and other diseases as well as in diagnostics.
Delenex Therapeutics Ag


07/07/16
20160194391 

Antibody derivatives


The invention relates inter alia to a bivalent, bispecific construct comprising an anti-il-6 antibody, or derivative thereof, and an anti-il-23 antibody, or derivative thereof and its use in therapy. The invention also relates to useful anti-il-6 and anti-il-23 antibodies..
Medimmune Limited


07/07/16
20160194389 

Fc-receptor binding modified asymmetric antibodies and methods of use


The present invention relates to antibodies and fc-region fusion polypeptides which are asymmetrically modified with respect to their fc-receptor, especially their fcrn, and methods of using the same.. .
Hoffmann-la Roche Inc.


07/07/16
20160194388 

Monoclonal antibodies to human 14-3-3 epsilon and human 14-3-3 epsilon sv


The present invention provides isolated antibodies that bind to 14-3-3 epsilon that are useful in the recognition of tumor cells and tumor specific delivery of drugs and therapies.. .
Washington University


07/07/16
20160194384 

Compositions and methods for the removal of biofilms


This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm.
Research Institute At Nationwide Children's Hospital


07/07/16
20160194383 

Anti-human respiratory syncytial virus (rsv) antibodies and methods of use


Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (f) protein of respiratory syncytial virus (rsv). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of rsv-mediated disease.
Crucell Holland B.v.


07/07/16
20160194382 

Means and methods for producing high affinity antibodies


The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like b-cells.. .
Aimm Therapeutics B.v.


07/07/16
20160194377 

Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof


The present invention discloses crystal structure of staphylococcus aureus clumping factor a (clfa) in complex with fibrinogen (fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of clfa targeted vaccines and therapeutic agents (including monoclonal antibodies).
The Texas A&m University System


07/07/16
20160193357 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an anti-trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hrs7 antibody.
Immunomedics, Inc.


07/07/16
20160193333 

Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists


The disclosure is directed to methods, treatment regimens, uses, kits and therapies for treating generalized pustular psoriasis (gpp). These methods, treatment regimens, uses, kits and therapies utilize, inter alia, administration of an il-17 antagonist, e.g., an il-17 antibody, such as secukinumab.
Novartis Ag


07/07/16
20160193332 

Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof


The invention relates generally to activatable antibodies that include a masking moiety (mm), a cleavable moiety (cm), and an antibody (ab) that specifically binds to epidermal growth factor receptor (egfr), and to methods of making and using these anti-egfr activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.. .
Cytomx Therapeutics, Inc.


07/07/16
20160193309 

Method to generate antibodies to ion channels


The present invention provides a method for generating a functionally modifying antibody to an ion channel comprising immunizing a host with a cyclic peptide comprising at least part of an extracellular sequence of said ion channel.. .
Ucb Biopharma Sprl


07/07/16
20160193295 

Stabilization of fc-containing polypeptides


This disclosure provides polypeptides comprising an antibody fc region having a deletion of one or more cysteine residues in the hinge region and substitution with a sulfhydryl-containing residue of one or more ch3-interface amino acids. Also, provided are fc-fusion proteins and antibodies containing said polypeptides, nucleic acids and vectors encoding said polypeptides, along with host cells and methods for making said polypeptides..
Amgen Inc.


07/07/16
20160193207 

Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria


Wherein q, y, r1, and r2 are as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided.

06/30/16
20160187355 

Detection and treatment of lrp4-associated neurotransmission disorders


The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (achr) and/or muscle specific tyrosine kinase (musk), the method including detecting autoantibodies that bind to lrp4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to lrp4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality.

06/30/16
20160187337 

Assay for jc virus antibodies


The disclosure relates to methods and reagents for analyzing samples for the presence of jc virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles hpvlps) under conditions suitable for binding of a jcv antibody in the sample to an hpvlp, and detecting the level of jcv antibody binding in the sample to hpvlp in one embodiment, determining the level of anti-jcv antibodies in the subject sample provides a method of identifying pml risk in a subject..

06/30/16
20160186202 

Axmi115 variant insecticidal gene and methods for its use


Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. The toxin coding sequences can be used in dna constructs or expression cassettes for expression in plants and bacteria.

06/30/16
20160185877 

Lox and loxl2 inhibitors and uses thereof


The present application relates to anti-lox and anti-loxl2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof.

06/30/16
20160185876 

Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy


A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human eno1 (genbank: aah50642.1), wherein the antibody comprises a light chain variable region (vl) domain comprising a cdr1 having the amino acid sequence lcdr1 (raseniysylt; seq id no: 6) and a cdr2 having the amino acid sequence lcdr2 (naktlpe; seq id no: 7) and a cdr3 having the amino acid sequence lcdr3 (qhhygtpyt; seq id no: 8) and an antibody heavy chain variable region (vh) domain comprising a cdr1 having the amino acid sequence hcdr1 (gytftscvmn; seq id no: 3), a cdr2 having the amino acid sequence hcdr2 (yinpyndgtkynekfkg; seq id no: 4) and a cdr3 having the amino acid sequence hcdr3 (egfyygnfdn; seq id no: 5), wherein framework regions in the light chain variable region (vl) domain and the heavy chain variable region (vh) domain comprise amino acid sequences from a human immunoglobulin.. .

06/30/16
20160185873 

Monoclonal antibodies for treatment of cancer


The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing gt468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung..

06/30/16
20160185869 

Anti-csf1r antibodies for treating pvns


Methods of treating pigmented villonodular synovitis (pvns) with antibodies that bind colony stimulating factor 1 receptor (csf1r) are provided.. .

06/30/16
20160185865 

Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use


The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor ccr4. This antibody is derived from mab 1567 and recognizes the same epitope.

06/30/16
20160185860 

Monoclonal antibodies against claudin-18 for treatment of cancer


The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing cld18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.. .

06/30/16
20160185859 

Anti-5t4 antibodies and uses thereof


Anti-5t4 antibodies, anti-5t4 antibody/drug conjugates, and methods for preparing and using the same.. .

06/30/16
20160185858 

Humanized antibodies to liv-1 and use of same to treat cancer


The invention provides humanized antibodies that specifically bind to liv-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting liv-1..

06/30/16
20160185857 

Novel anti-fc-gamma receptor iib antibodies and uses thereof


The present invention provides an anti-fcyriib antibodies which, in comparison to prior art antibodies, markedly increase itim phosphorylation of fcyriib and can thus be used for the treatment or prophylaxis of autoimmune diseases.. .

06/30/16
20160185856 

Anti-claudin 1 antibodies and uses thereof


The present invention relates to anti-claudin 1 antibodies and their uses thereof. In particular, the present invention relates to an anti-claudin 1 (cldn1) antibody comprising n heavy chain variable region comprising seq id no:2 in the h-cdr1 region, seq id no:3 in the h-cdr2 region and seq id no:4 in the h-cdr3 region; and a light chain variable region comprising seq id no:6 in the l-cdr1 region, seq id no:7 in the l-cdr2 region and seq id no:8 in the l-cdr3 region..

06/30/16
20160185855 

Anti-lrp5 antibodies and methods of use


The invention provides anti-lrp5 antibodies and methods of making and using the same.. .

06/30/16
20160185853 

Cancer treatment using antibodies that bind cell surface grp78


This application provides, inter alia, antibodies or antigen-binding fragments thereof, targeting cell surface grp78 expressed on tumor cells, tumor endothelial cells, and tumor initiating cancer cells. These anti-grp78 antibodies, or antigen-binding fragments thereof, have a high affinity for grp78 and are less immunogenic compared to their unmodified parent antibodies in a given species, e.g., a human, and function to inhibit grp78.

06/30/16
20160185852 

Anti-notch3 antibodies


Monoclonal antibodies that bind and inhibit activation of human notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of notch3..

06/30/16
20160185851 

Antibodies to interleukin-6 and use thereof


The present disclosure provides antibodies that bind to human interleukin-6 (il6). The antibodies can modulate il6 signaling and thus used in treatment or prevention of il6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (ra), angiogenesis, and cancer..

06/30/16
20160185850 

Stable and soluble antibodies inhibiting tnf alpha


The present invention relates to particularly stable and soluble scfv antibodies and fab fragments specific for tnfα, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of tnfα, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of tnfα-related disorders.

06/30/16
20160185849 

Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease


Multiple-variable dose methods for treating tnfα-related disorders, including crohn's disease and psoriasis, comprising administering tnfα inhibitors, including tnfα antibodies, are described. Multiple-variable dose methods include administration of a tnf-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the tnf-inhibitor is administered in a higher dosage during the induction phase..

06/30/16
20160185847 

Use of monoclonal antibodies for the treatment of inflammation and bacterial infections


A composition includes monoclonal antibodies directed against a circulating proinflammatory cytokine, the antibodies having a high affinity for the fcγriiia receptor (cd16), in particular the fucose level of all of the antibodies of the composition being less than 60%, and preferably less than 50%, and in particular, the galactosylation level of all of the antibodies of the composition being at least 60%, for the use thereof in the context of the prevention or treatment of the early phases of inflammation. A composition including monoclonal antibodies directed against a circulating bacterial toxin, having an improved affinity for the fcγriiia receptor (cd16) with respect to antibodies directed against the bacterial toxin, produced in the cho cell line, for the use thereof in the context of the prevention or treatment of the early phases of a bacterial infection linked to the release of the toxin is also described..

06/30/16
20160185846 

Antibodies against monocyte chemotactic proteins


The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins mcp-1, mcp-2 and mcp-3. The invention also provides cells producing the antibodies, and methods of making and using the same..

06/30/16
20160185841 

Method for purifying antibodies using pbs


Disclosed here includes a method for purifying a biologic composition, comprising diafiltering the biologic composition into a composition comprising phosphate buffered saline (pbs) to obtain a purified composition. The method disclosed here can be particularly useful for removing one or more impurities from the biologic composition, such as bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (bis-tris)..

06/30/16
20160185830 

Axmi440 toxin gene and methods for its use


Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided.

06/30/16
20160185827 

Vaccines for preventing meningococcal infections


The present invention stems from the finding that the interaction between the β2 adrenoceptor (β2ap) and type iv pilus-associated proteins initiates a process leading to the opening of the blood-brain barrier. The invention therefore pertains to a vaccine for preventing the spreading of meningococci into the meningeal space, wherein said vaccine allows the production of antibodies inhibiting the interaction between the type iv pilus-associated proteins and the β2ap..

06/30/16
20160185825 

Engineered outer domain (eod) of hiv gp120 and mutants thereof


The invention relates to an engineered outer domain (eod) of hiv gp120 and mutants thereof and methods of making and using the same. The mutant eods may be advantageous for the elicitation of cd4-binding site (cd4bs)-directed broadly-neutralizing antibodies (bnabs) and/or improve binding to mature vrc01 and/or improve binding to germline vrc01 and the germlines of other vh1-2 derived broadly-neutralizing antibodies.

06/30/16
20160184453 

Carrier-antibody compositions and methods of making and using the same


Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic..

06/30/16
20160184452 

Carrier-antibody compositions and methods of making and using the same


Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic..

06/30/16
20160184450 

De-n-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy


The present invention generally provides compositions methods and composition relating to the diagnosis and/or treatment of cancers having a cell surface de-n-acetylated sialic acid antigen, e.g., an at least partially de-n-acetylated ganglioside and/or a de-n-acetylated sialic acid-modified cell surface protein.. .

06/30/16
20160184421 

Immunotherapeutic targets against staphylococcus aureus


The subject invention pertains to vaccine formulations and antibodies, and related methods, for the treatment and/or prevention of s. Aureus infection.

06/30/16
20160184415 

Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens


Compositions useful to induce anti-taca immune response and kits comprising the same and methods of using the compositions to treat and prevent cancer are disclosed. Isolated human antibodies which bind to a carbohydrate mimetic peptide and methods of making the same and using the same to treat and prevent cancer are disclosed.

06/30/16
20160184405 

Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy


The present invention provide purified flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.. .

06/30/16
20160184339 

Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells


Methods are provided herein for use of e-selectin antagonists for mobilizing cells, such as hematopoietic cells, hematopoietic stem cells and progenitor cells, white blood cells, and malignant cells, and hematopoietic tumor cells from the bone marrow. More specifically, methods are provided for using e-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers, and peptides for mobilizing cells from the bone marrow to the peripheral vasculature and tissues..

06/30/16
20160184256 

Method of treating disorders of the cardiovascular system and a pharmaceutical agent


Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too..

06/30/16
20160184229 

Carrier-antibody compositions and methods of making and using the same


Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic..

06/23/16
20160178634 

Method for predicting cancer sensitivity


The present invention relates to methods of determining cancer cell sensitivity to treatment by using antibodies to detect the presence of heterodimers comprising bcl-2 proteins or caspase-iap proteins in the cell. The invention also provides a method of predicting therapeutic efficacy in a cancer patient..

06/23/16
20160178626 

Human streptococcus pneumoniae antibodies and uses therefor


The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of streptococcus pneumoniae infections. In particular, these antibodies may kill streptococcus pneumoniae or limit the replication of streptococcus pneumoniae.



Antibodies topics: Antibodies, Recombinant, Nucleic Acid, Nucleic Acids, Polypeptide, Therapeutics, Immunoglobulin, Immunoglobulins, Monoclonal, Radiation Therapy, Desmoplastic, Hypertension, Hypertensive, Immunotherapy, Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antibodies for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibodies with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.44

4668

3 - 0 - 101